Event Overview

This 3-day forum is the “must attend” event for those senior decision-makers looking to drive their medical affairs teams and departments and enhance their KOL & stakeholder engagement at all levels.

The first day will feature several keynote presentations from VP-Level thought leaders on shaping and leading the medical affairs departments, justifying medical affairs performance through innovative metrics and tracking effectiveness of the function as an essential element of today’s pharmaceutical companies. They will be discussing the strategic drivers for medical affairs, and guidance on how to make best use of this vital function.

Day 2 of the Forum will feature 2 specific streams depending on your specific needs:

Stream 1:Real-World Evidence Generation for Medical Affairs – Generating real world evidence via observational studies and the use of patient registries is one of the fastest growing areas of pharmaceutical R&D. Such post-marketing studies are becoming increasingly important as regulatory agencies and payers demand more long-term data which demonstrates efficacy, safety and quality. The Medical Affairs unit plays a decisive role in generating this vital evidence and this stream will present solutions to the challenges companies face in generating high-quality evidence which will communicate a compelling value argument to all necessary stakeholders.

Stream 2:Enhancing Medical Communications for Medical Affairs – Medical Affairs departments are increasingly looking to implement next generation medical communication practices, to offer essential evidence-based information to stakeholders on demand, through a variety of classical, yet also increasingly digital channels. This stream will focus on two key aspects of medical communication. Firstly, issues such as: protocol writing for internal late-phase studies and research initiatives; working with External Experts (KOLs) to enhance publications, abstracts & posters and receiving proposals for investigator-initiated studies. The second section of this day will focus on Medical Scientific Marketing communications, including the review process, compliance issues, ensuring the claims made by marketing colleagues are justified and appropriately communicated and also effectively localized from global-level to country-level market requirements.

Day 3: Best Practices in Medical Science Liaison – This day will feature best practice case studies on structuring, managing, and monitoring the evolving Medical Science Liaison role within your organisation. This meeting is an ideal chance to benchmark with other market leaders in this field who are utilising the unique MSL function to more effectively communicate with external experts, engage them with advanced science and demonstrate product evidence. All attending will discovery how MSLs can help regain the credibility of the pharmaceutical industry as a value-adding partner to the healthcare ecosystem.

Along with our exclusive networking dinner for all participants, the event will feature excellent networking opportunities and the chance to strengthen your contacts within the Medical Affairs community. The 2017 event was a sell-out so please make sure you book early to avoid disappointment.
We look forward to meeting you in London!

Speakers List

Industry Experts

SVP, Head Worldwide Medical Affairs
GSK, UK

Head of Cardiovascular Development – Therapeutic Area Head
Bristol-Myers Squibb, USA

SVP Head Clinical Development
BTG International, UK

Vice President, Global Head of Selling Excellence
GSK, UK

Senior Director, Group Lead PEH HEOR
Patient and Health Impact
Pfizer, USA

Senior Director, Medical Affairs Lead - CV/Metabolism - Emerging Markets
Pfizer, USA

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

VP and Head of Medical Affairs EU/RoW
Jazz Pharmaceuticals, UK

Former Senior Director, Medical Affairs Oncology
Pierre Fabre Laboratories, France

 

Executive Medical Director Head of Medical Affairs for European Mid-Size Markets
Amgen, Austria

Lead, National Managed Care Liaisons PACE (Patient Access Collaboration and Exchange)
Genentech, USA

Director of Global MSL Practices & Medical Training
GSK

Medical Director
SLA Pharma, UK

National Director – Health Economics & Outcomes Research,
Medical Affairs, Americas
Astellas, USA

European Medical Director
Norgine, UK

Market Access Director
Medicines for Europe, Belgium

Senior Director, Global Scientific Affairs
Luminex Corporation, USA

Medical Affairs Director, World Business Line
Air Liquide Healthcare International, France

Non-Industry Stakeholders

Alternate Patient member of the
EMA Committee on Advanced Therapies (CAT)
Patient Advocate, Belgium

Ambassador, Genetic Alliance, UK
Member, NHS England Rare Diseases Advisory Group

President
HealthCore, (an Anthem Inc. Company), USA

Medical Oncologist
The European Society for Medical Oncology (ESMO), Italy

Experienced Solution Providers

General Manager
Tardis Medical Consulting, UK

Corporate VP, Observational Research
PAREXEL

Director
PharmaReview, UK

Principal Consultant, (Pricing and Market Access)
Parexel, UK

Annie Rankin

Client Partnerships Lead
Succinct Medical Communications

Managing & Scientific Director
MediNeos

Katie Corbin

Managing Director
Succinct Medical Communications

Deputy Chief Health Officer
IBM Watson Health

Gavin Kenny

Account Director
Succinct Medical Communications

Senior Scientific Director
Complete HealthVizion

Richard Jones

Patient Services Director
The Earthworks (an OPEN Health Company)

Director of Scientific Services
Complete HealthVizion

Project Director, Real World & Late Phase
Syneos Health

Event Structure

Photo Gallery

Event Program

MedAffairs: Strategy & Capabilities

Day 1 - 27th February, 2018
8.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks:

SVP, Head Worldwide Medical Affairs
GSK, UK

CAPABILITIES DEVELOPMENT GLOBAL & LOCAL BEST PRACTICES

09.10
Capabilities development & implementation: Global perspective

SVP, Head Worldwide Medical Affairs
GSK, UK

09.50
Medical affairs evolution and differences between US and European approaches
  • The evolution of the medical affairs function
  • How different is the US regulatory environment?
  • Developing a medical affairs strategy
  • Lessons learned

Former Senior Director, Medical Affairs Oncology
Pierre Fabre Laboratories, France

 

10.30
Capability development in emerging markets: Differences & similarities
  • Emerging Markets dynamics with regards to medical affairs function & capabilities needed.
  • Differences and similarities between EM and the rest of the world in terms of capabilities needed.
  • Challenges pertinent to EM regarding capability development.
  • Experience sharing from initiatives lead in the past.

Senior Director, Medical Affairs Lead - CV/Metabolism - Emerging Markets
Pfizer, USA

11.10
Networking & Coffee Session - Sponsored by:
11.40
Better leveraging your HEOR function: Value generation & communication in the real-world setting
  • Provide a strategic and overarching understanding of the value of HEOR to medical affairs.
  •  Help broaden the understanding of the HEOR and Medical partnership on strategic evidence generation and value communication.
  • Understand basic strategic framework design, development, value, and execution of a health economics and outcomes research program throughout a product lifecycle.
  • Share and illustrate via a real-world case example on how to establish value.

Senior Director, Group Lead PEH HEOR
Patient and Health Impact
Pfizer, USA

12.20
AI, RWE and the Future of Healthcare
  • Discuss the growing data challenges in healthcare
  • Review components of health and associated data
  • Discuss RWE and its role in healthcare decision making
  • Describe how AI can be applied to diverse data sets for new insights

Deputy Chief Health Officer
IBM Watson Health

13.00
Luncheon Break

CAPABILITIES DEVELOPMENT IN NICHE AREAS

14.00
Medical affairs in diagnostics: How different is it?
  • Building a medical affairs team in diagnostics.
  • Is a different skill set needed?
  • Delivering medical value in diagnostics.
  • Working together with pharma.

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

14.30
Demonstrating the value of medical affairs to internal stakeholders in small to mid-sized companies
  • Review various activities led by Medical Affairs that can create value for the customer.
  • Share examples of how the work of Medical Affairs directly contributes to the company’s revenue and the customer experience.
  • Discuss metrics, such as ROI and CLV, that can be used to measure and describe the value of Medical Affairs to internal stakeholders in the language they understand.

Senior Director, Global Scientific Affairs
Luminex Corporation, USA

15.00
Increasing the efficiency of your Medical Affairs Team: The Silent Time Killer of Copy Review
  • Case Study: How outsourcing can unburden your team to focus on
    value-adding relationships

Director
PharmaReview, UK

15.30
Networking & Coffee Session - Sponsored by:
15.50
Panel discussion: The Impact of internal stakeholders on medical affairs capabilities development
  • Managing cross functional teams i.e. clinical/ regulatory/commercial/market access.
  • Which skills are required from medical affairs professionals today in order to co-operate with internal stakeholders?
  • Unique medical affairs HR plans for talent recruitment and retention.

Head of Cardiovascular Development – Therapeutic Area Head
Bristol-Myers Squibb, USA

SVP Head Clinical Development
BTG International, UK

Senior Director, Group Lead PEH HEOR
Patient and Health Impact
Pfizer, USA

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

Vice President, Global Head of Selling Excellence
GSK, UK

16.40
Panel discussion: Optimising cooperation with external stakeholders: Understanding their expectations and requirements
  • Understanding external stakeholders’ new requirements.
  • How can the pharma industry satisfy them all?
  • How does this affect medical affairs goals, definitions and structure?

Former Senior Director, Medical Affairs Oncology
Pierre Fabre Laboratories, France

 

Alternate Patient member of the
EMA Committee on Advanced Therapies (CAT)
Patient Advocate, Belgium

Ambassador, Genetic Alliance, UK
Member, NHS England Rare Diseases Advisory Group

President
HealthCore, (an Anthem Inc. Company), USA

Medical Oncologist
The European Society for Medical Oncology (ESMO), Italy

17.30
Chairperson’s Closing Remarks
17.40
End of Day One
18.30
Exclusive Complimentary Networking Dinner for all event participants

MedAffairs: Real-World Evidence

Day 2 - Stream 1 - 28th February, 2018
08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks:

Project Director, Real World & Late Phase
Syneos Health

BALANCING INTERNAL & EXTERNAL STAKEHOLDERS’ RWE REQUIREMENTS

09.10
Answering internal stakeholder’s needs through novel approaches to RWE development

Head of Cardiovascular Development – Therapeutic Area Head
Bristol-Myers Squibb, USA

09.40
The changing trends in real-world Evidence

Project Director, Real World & Late Phase
Syneos Health

10.10
Strategic use of real-world evidence
  • Why Real World Data?
  • Evidence generation as a strategic choice.
  • Role of trends.
  • Data and Big Data.
  • Converting information to wisdom.

Executive Medical Director Head of Medical Affairs for European Mid-Size Markets
Amgen, Austria

10.40
Networking & Coffee Session - Sponsored by:
11.10
Promoting the patient voice in evidence generation and global market access planning
  • Regulator and payer perspectives on patient-centric data in decision making.
  • Highly successful strategies for leveraging the patient voice in RWE research.

Corporate VP, Observational Research
PAREXEL

Principal Consultant, (Pricing and Market Access)
Parexel, UK

11.40
Evidence development: Is the patient really the centre point of attention?
PATIENT PERSPECTIVE
  • How early should patients be involved in research decisions?
  • Do patients have a say in the market authorisation process?
  • Are patients involved enough in HTA & reimbursement decisions?

Alternate Patient member of the
EMA Committee on Advanced Therapies (CAT)
Patient Advocate, Belgium

12.10
The art and science of designing a RWD project
  •  The hidden link between product strategy and scientific approach
  • Challenges and opportunities in dealing with many stakeholders
  • Prioritizing multiple interests in one “finer” research question
  • A project design workflow for clinical research with RWD

Managing & Scientific Director
MediNeos

12.40
Luncheon Break

TAKING TRAINING & EDUCATION TO THE NEXT LEVEL

13.40
Accelerating the development of relevant evidence for payers and regulators – Evolution or Revolution?
PAYER PERSPECTIVE

The gap in evidentiary requirements between regulatory and postapproval decisions has increasingly become a concern and is seen as a core contributor to an unsustainable healthcare model in the US. As real-world data increases and research methods utilization these data sources mature, payers and now regulators are beginning to focus more attention on the potential contribution of real-world evidence for closing this evidence gap. This presentation will outline the evolution of research designs and the potential for revolutionary changes in the research process over the next 5 years and point out key challenges to overcome to effectively close this gap.

President
HealthCore, (an Anthem Inc. Company), USA

14.20
How can doctors be better engaged in evidence generation?
PHYSICIAN PERSPECTIVE

Medical Oncologist
The European Society for Medical Oncology (ESMO), Italy

15.00
Networking & Coffee Session - Sponsored by:
15.30
Panel discussion: Leveraging real-world evidence to make a meaningful difference to your product value
  • Demonstrating the ROI of RWE to internal stakeholders.
  • Strategies for small/medium pharma to generate RWE on limited budgets.
  • Motivating academically-focused investigators for commercially focused studies.
  • Incorporating HEOR endpoints into Phase III and IV studies.
  • Integrating IIT into your post-marketing development strategy.
  • The increasing use of eHealth and Big data.

Head of Cardiovascular Development – Therapeutic Area Head
Bristol-Myers Squibb, USA

Executive Medical Director Head of Medical Affairs for European Mid-Size Markets
Amgen, Austria

President
HealthCore, (an Anthem Inc. Company), USA

Medical Oncologist
The European Society for Medical Oncology (ESMO), Italy

Corporate VP, Observational Research
PAREXEL

16.20
Chairperson’s Closing Remarks
16.30
End of Day Two

MedAffairs: Communications

Day 2 - Stream 2 - 28th February, 2018
08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks:
Annie Rankin

Client Partnerships Lead
Succinct Medical Communications

UTILISING MEDICAL COMMUNICATION TO ACHIEVE INNOVATION & IMPROVED OUTCOMES

09.10
Understanding patient needs: How can pharma manufacturers co-operate and communicate better with patients?
PATIENT PERSPECTIVE

Ambassador, Genetic Alliance, UK
Member, NHS England Rare Diseases Advisory Group

09.40
Appreciate pharma/payer trends that offer optimal Impactful communication tactics

Addressing optimizing pharma/payer communications by understanding key trends:

  • Understand development costs and physician, patient and clinical decision making when approaching the marketplace (including precision medicine).
  • Examine the rising cost of specialty products due to innovation, aging and expanding marketplaces and societal decision making.
  • Discuss innovative strategies that can analyze and predict patient behavior and improve outcomes.
  • Leverage technology to tailor engagement, assess patient adherence and drive better outcomes.

Lead, National Managed Care Liaisons PACE (Patient Access Collaboration and Exchange)
Genentech, USA

10.10
Multichannel strategy and behavioural science: perfect partners for smarter communications
  • Appreciate the importance of understanding human behaviour in designing effective and affective medical communications
  • Recognise the synergistic benefits of bringing behavioural insights and multichannel strategy together for smarter, more targeted communications
  • Challenge your communications strategy: not doing things ‘because we’ve always done it this way’, looking critically at the end goals, the behavioural context and barriers, and designing a smart multichannel strategy

Senior Scientific Director
Complete HealthVizion

Director of Scientific Services
Complete HealthVizion

10.50
Networking & Coffee Session - Sponsored by:
11.20
The power of consistent communication with HCPs and patients
  • Keeping consistency in communications with both HCPs and patients to maximise high quality patient-HCP conversations
Katie Corbin

Managing Director
Succinct Medical Communications

Richard Jones

Patient Services Director
The Earthworks (an OPEN Health Company)

12.00
eLeaflets, patients communities and improved health outcomes
  • Learn how to create the value beyond the pill by enabling patientcentred healthcare.
  • How can social platforms gain insights in patient experiences and quality of life?
  • A single trusted source for a 2-way patient information sharing.

Market Access Director
Medicines for Europe, Belgium

12.40
Luncheon Break

MEDICAL COMMUNICATIONS IN SMALLER PHARMA

13.40
Medical communication: Pharma contribution to research
  • How does medical communication contribute to innovation?
  • Real life case studies.

Medical Director
SLA Pharma, UK

14.20
Medical affairs accountability for the business strategy in a small/medium healthcare company
  • Which capabilities and skills are needed in a small medical affairs department?
  • What are the pillars of performance and how to process them (Information, Communication, External relations)?
  • How to structure required resources to the medical governance and the transversal support needed by marketing and R&D team?

Medical Affairs Director, World Business Line
Air Liquide Healthcare International, France

15.00
Networking & Coffee Session - Sponsored by:
15.30
Panel discussion: Communications management: From external stakeholders to internal functions and the other way around
  • Aligning the value message through internal and external medical communications.
  • Understanding KOLs/External Experts and stakeholder.
  • Communication needs: How effective is the shift to digital KOL communication?
  • Patient-centricity in communications.
  • Medical communications ethics & compliance issues.

Lead, National Managed Care Liaisons PACE (Patient Access Collaboration and Exchange)
Genentech, USA

Medical Director
SLA Pharma, UK

Market Access Director
Medicines for Europe, Belgium

Medical Affairs Director, World Business Line
Air Liquide Healthcare International, France

Ambassador, Genetic Alliance, UK
Member, NHS England Rare Diseases Advisory Group

16.20
Chairperson’s Closing Remarks
16.30
End of Day Two

MedAffairs: MSL Management

Day 3 - 1st March, 2018
08.00
Registration & Coffee
08.30
Chairperson’s Opening Remarks

VP and Head of Medical Affairs EU/RoW
Jazz Pharmaceuticals, UK

NEXT GENERATION MSL CAPABILITY DEVELOPMENT

08.40
The evolution of the MSL

Unprecedented changes in the healthcare landscape is forcing a broader role for Medical Science Liaisons. We’ll learn about the trend toward increasing the relevance of MSLs in supporting complex products in a complex marketplace.

  • A complex marketplace drives a new and broader set of stakeholders
  • Expectations of field medical are increasing
  • Capabilities needed for MSLs to address marketplace demands are changing

National Director – Health Economics & Outcomes Research,
Medical Affairs, Americas
Astellas, USA

09.15
The right MSL role balance: Challenges and real-life experiences
  • R&D Vs. Commercial orientation.
  • What is the impact of the team’s structure on performance?
  • The use of technology to capture critical information from MSLs activities.

Director of Global MSL Practices & Medical Training
GSK

09.50
How to build a medical affairs organisation in a biotech company – real world experience!
  • Setting a vision.
  • Priorities and challenges.
  • Building capabilities and competencies across the department.
  • Measuring success.

VP and Head of Medical Affairs EU/RoW
Jazz Pharmaceuticals, UK

10.20
Networking & Coffee Session
10.50
An aligned and successful European MSL team
  • The term MSL has varied connotations in different EU countries.
  • Creating a European MSL team with shared vision and goals.
  • Challenges, opportunities and rewards.

European Medical Director
Norgine, UK

11.20
Leading MSLs to the best of their potential
  • Internal training
  • Engagement tool
  • Keeping the conversation going
Annie Rankin

Client Partnerships Lead
Succinct Medical Communications

Gavin Kenny

Account Director
Succinct Medical Communications

11.50
Panel discussion: Next generation MSL capability development
  • Which new capabilities are required from MSLs today and will be in the future?
  • What has to change internally to enable MSL success?
  • The emerging importance of health outcomes liaison.
  • Capabilities and reskilling training.

Director of Global MSL Practices & Medical Training
GSK

National Director – Health Economics & Outcomes Research,
Medical Affairs, Americas
Astellas, USA

European Medical Director
Norgine, UK

General Manager
Tardis Medical Consulting, UK

Annie Rankin

Client Partnerships Lead
Succinct Medical Communications

12.30
Luncheon Break

INTERACTIVE WORKSHOP

13.30
Excellence in MSL Leadership and Development

Experience an engaging and interactive mix of presentation and breakout scenarios from one of the industry’s most experienced MSL Management
consultants. With real-world examples of handling difficult and challenging experiences which MSL Managers and Leaders face, this workshop will give participants a chance to benefit from the ability to step outside of their role and assess how they handle their vital internal interactions to get the most from their teams.

General Manager
Tardis Medical Consulting, UK

16.00
Chairperson’s Closing Remarks
16.10
End of Day Three

Event Partners

Speaker Biographies

Danie du Plessis

SVP, Head Worldwide Medical Affairs
GSK, UK

Danie du Plessis was appointed Senior Vice President, Head Worldwide Medical Affairs, effective November 2015. In this role he is accountable for medical affairs and governance across the Europe, Emerging Markets & Australasia, US and Japan regions and continues to be based at GSK House in the UK. Danie joined GSK in May 2010 as VP, Medical Affairs, Emerging Markets & Asia Pacific and Japan, served as interim Regulatory Head for Emerging Markets & Asia Pacific in 2011 and also served as Senior Vice President, International Medical in 2013. He previously worked for Eli Lilly & Company for 17 years in different roles and different therapeutic areas. He joined Eli Lilly as a clinical research physician in the South African affiliate, where he also completed a 2 year Sales and Marketing assignment. After 2 ½ years as Medical Manager of South Africa and Sub-Saharan Africa, he joined the UK affiliate in October 2001 as Associate Medical Director before moving to a role in Global Product Safety in May 2003. In August 2005, Danie was appointed Director for Clinical Operations and Information Sciences in Europe and became Medical Director for Australia and New Zealand in 2007. Prior to joining GSK, he was Senior Director, Medical Affairs for Emerging Markets in Lilly. Danie holds a Medical Degree from the University of Stellenbosch and a Masters degree in Pharmacology from the University of the Free State in South Africa. He also holds an MBA from the Edinburgh Business School in Scotland.

Christoph Koenen

Head of Cardiovascular Development – Therapeutic Area Head
Bristol-Myers Squibb, USA

Dr. Koenen is currently heading all cardiovascular development as well as CV Medical within BMS.

Christoph joined BMS in 2011 and has worked in different medical and development functions in Europe as well as in the US.

He joined BMS from Novo Nordisk were his last position was Vice President and Head of Global Medical Affairs. During his 9 years with Novo Nordisk Christoph has worked on the development of several compounds for Novo Nordisk including three different insulin compounds as well as launched several compounds successfully.

Before joining Novo Nordisk in 2002, Christoph worked for GlaxoSmithKline in London, UK as well as in Germany. While at GlaxoSmithKline, Christoph was responsible for the development of anti-diabetic compounds. 

Christoph received his medical degree from Ruprecht-Karls University School of Medicine in Heidelberg, Germany in 1994. He also holds a Master of Business Administration from Schiller International University.  In addition to attending Heidelberg Medical School, Christoph attended medical school in Johannesburg, South Africa, Basel Switzerland and Columbia, Missouri, USA.

As a board-certified internist and diabetologist, Christoph has researched the influence of ACE-Inhibitors on diabetic nephropathy, as well as the effect of insulin treatment on weight gain in obese type 2 diabetes patients.

 

Nermeen Varawalla

SVP Head Clinical Development
BTG International, UK

As Senior Vice President and Head of Clinical Development, BTG International a listed global medical technology business focussed on interventional therapies, Nermeen leads a team of 55 staff with responsibility for the clinical development of the product portfolio encompassing the specialty pharmaceutical and interventional oncology, vascular & pulmonology business units. Dr Varawalla completed her undergraduate and specialist medical training at the University of Mumbai, before receiving a Rhodes Fellowship to the University Oxford where she obtained her doctorate from the Institute of Molecular Medicine. She is a Fellow of the Indian College of Physicians & Surgeons, a Member of the Royal College of Obstetrics and Gynaecology and holds a Royal College of Radiology Diploma in Advanced Obstetric Ultrasound. After her career in academic medicine Nermeen completed an MBA at INSEAD. Following which she worked at Accenture’s UK Life Science & Healthcare Strategy Consulting. She then established two successful clinical trial ventures. One was acquired by a global player PRA International where Nermeen then held numerous leadership roles. More latterly she raised private equity financing to found ECCRO, a differentiated India specialist clinical trials business. Nermeen then joined one of ECCRO’s clients as Executive Vice President, Global Clinical Development within the Intas Group, a high growth specialty pharmaceutical business. Nermeen serves as a Trustee of the Malaria Consortium, a UK headquartered, non-profit organisation that delivers global health solutions focussed on the control of malaria and other neglected tropical diseases.

Court Horncastle

Vice President, Global Head of Selling Excellence
GSK, UK

Court Horncastle is VP & Global Head of Selling Excellence at GSK.  He leads a team that focuses on driving sales effectiveness to the top 25% compared to peers in GSK’s most important markets. Prior to his current role, Court was a member of GSK’s Canadian Pharma Leadership Team for 3 years.  His responsibilities included leading the Classic and Established Products, Specialty and New Products Business Unit, all Digital initiatives across the enterprise and leadership of the Sales Force. Since joining GSK in 1992 as a Sales Representative in the U.S., Court earned positions of increasing responsibility in a variety of Commercial roles.  Previous roles at GSK included Executive Director, Corporate Strategy & Office of the CEO based in the UK and Area VP for Integrated Delivery Networks in the United States. Court holds a Bachelor’s Degree from Vanderbilt University.  He is also a graduate of the Transformational Leadership program at The Wharton School, University of Pennsylvania.

Seema Haider

Senior Director, Group Lead PEH HEOR
Patient and Health Impact
Pfizer, USA

Seema Haider has over twenty-two years of experience in leading and managing international, multidisciplinary teams for the lifetime management of developing and executing Outcomes Research (OR) and Access Product and Therapeutic Area Portfolio strategies, studies and publications. Seema received her MSc in Social and Preventive Medicine from University of Montreal in 1992. From 1993 through1995, Seema completed PhD course work in Social and Preventive Medicine, specializing in Pharmacoeconomics, led a prospective, multicenter, Pharmacoeconomics substudy in COPD patients at the Randomized Clinical trial Unit at McGill University and was Project Director at the Interdisciplinary Health Research Group, Heath economics Unit at the University of Montreal. From 1995 to 1998, Seema was Country Manager of Pharmacoeconomics and Quality of Life Research at Schering Plough Canada for all products.
Seema joined Pfizer Inc., 19 years ago and with escalating leadership positions, she currently leads Health Economics and Outcomes
Research, Patient & Health Impact, for the Pfizer Essential Health Business Unit. Her work has been extensively presented and featured at conferences worldwide and in publications in high impact peer reviewed journals. Seema has also contributed to several training
initiatives worldwide including, the IFAPP-King’s College London
Medical Affairs in Medicines Development Professional Certification Program and is an International Advisor to the ISPOR India Chapter.
Outside of work, Seema is passionate about the non-profit community
work she does through GraceCares in rural India. She currently resides
in Boston, MA, USA with her family.

Emre Aldinc

Senior Director, Medical Affairs Lead - CV/Metabolism - Emerging Markets
Pfizer, USA

Dr. Emre Aldinç is currently the Cardiovascular/Metabolism Medical Affairs Lead for Emerging Markets at Pfizer, based in New York Headquarters. Dr Aldinç completed his medical training at Hacettepe University School of Medicine and his training in orthopaedic surgery
at Gazi University School of Medicine, both in Ankara, Turkey. Dr Aldinç
started his pharmaceutical industry career in 2008 at Pfizer Turkey; he was the Asia-Pacific Medical Affairs Director for Cardiovascular and Pain/Neuroscience therapeutic areas before his current position. He has been involved in clinical studies in areas including anticoagulation for the prevention of postoperative VTE, besides others in the scope of orthopaedic surgery. He was the official team physician of the Turkish national volleyball teams and health committee member of the Turkish Volleyball Federation between 2004 and 2007.

Albert Jan Schutte

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

AJ qualified as an MD at the Free University of Amsterdam (NL) and worked several years in Internal Medicine in Amsterdam. In 2008 he joined Roche in Basel from Schering-Plough/Organon in New Jersey
to take over the leadership of the Ocrelizumab Multiple Sclerosis
Life Cycle team. In February 2013 he was appointed Therapeutic
Area Head Medical Affairs Neuroscience/Cardio-Metabolism and
in October 2015 he took the opportunity to build and lead the Medical Affairs Team at Roche Diagnostics in Rotkreuz. He started his career in Pharma as a Medical Advisor CNS with Solvay Pharma in the Netherlands working in Depressive and Anxiety Disorders. After several years of operational work at the affiliate level he joined Solvay
Pharma International as Medical Manager Middle East and Asia Pacific. In 1998 he joined Organon International where he predominantly worked in Neuroscience (depression, bipolar disorders, schizophrenia) and developed experience across the value chain being involved in Strategy Development from Proof of Concept to the implementation of Medical Strategy at affiliate level. In 2002 he joined the US Headquarters where he was Executive Director Neuroscience, both as Global Marketing Director and Global Medical Affairs Lead.

Kelvin Tan

VP and Head of Medical Affairs EU/RoW
Jazz Pharmaceuticals, UK

Kelvin graduated from the University of Wales, College of Medicine with a Medical Degree and a Bachelor of Science degree in Medical Biochemistry from University College Cardiff. He underwent training in Paediatrics and is a Member of the Royal College of Paediatrics and Child Health. Having spent 3 years as a clinical research fellow at the University of Nottingham, he then transitioned into the pharmaceutical industry, where he has held a variety of roles in Medical Affairs and Clinical Development, for several companies around the world, gaining experience in specialty and rare/orphan disease areas.  Kelvin most recently joined Jazz Pharmaceuticals, some three years ago, as Vice President of Medical Affairs EU/RoW.

Marcello Riggi

Former Senior Director, Medical Affairs Oncology
Pierre Fabre Laboratories, France

 

Marcello is the former Medical Affairs Director of Pierre Fabre Medicaments,  in charge of the international Life Cycle Management of the Oncology Pipeline. Marcello has more than twenty-five years’ experience in the pharmaceutical field, where he gained a long practice in Clinical Development, Regulatory, Market Access, and understanding the national policies related to the management of the cancer patient. Before joining the Pharma Industry he worked as oncologist involved in pre-clinical and clinical research, including a five-year experience at the Institut Gustave Roussy, Villejuif. Marcello Riggi is MD and obtained PhDs in Surgical and Medical Oncology.

Jacek Nowak

Executive Medical Director Head of Medical Affairs for European Mid-Size Markets
Amgen, Austria

Jacek Nowak is Amgen’s Executive Medical Director for European Mid-Size Markets. Jacek has been active as biopharmaceutical industry leader for over 25 years.

Prior to joining Amgen in 2003, Jacek served as Medical Director for Central Europe with Wyeth. He had also held a role of Marketing and Sales Manager with Cilag and prior to that he worked as a medical doctor at the Cardiology and Intensive Care Unit at the University Hospital of the Silesian School of Medicine in Katowice, Poland.

Jacek holds a degree of medical doctor and earned his doctorate on research work on leptin receptor polymorphism. Jacek holds a Diploma in Pharmaceutical Medicine from the Royal College of Physicians in London. Jacek’s expertise pertains to area of organ transplantation, oncology, cardiology and metabolic disorders.

Susan Malecha

Lead, National Managed Care Liaisons PACE (Patient Access Collaboration and Exchange)
Genentech, USA

Susan Malecha has over twenty-six years of pharmaceutical/biotechnology industry experience in medical affairs, new product development, managed markets, medical education, medical science liaison and management experience. She graduated with a BS in Pharmacy from Butler University, completed her Doctor of Pharmacy at University of Illinois at Chicago, and earned her Masters of Business Administration. She recently completed certificate programs for Pharmacoeconomics Health and Outcomes Research from University of Washington and Building and Leading Effective Teams from Columbia University. She currently is the Lead, National Managed Care Liaisons in Medical Affairs at Genentech. She was the Sr. Director, BioOncology MSLs at Genentech, Sr. Director of a clinical field based team, Director of Managed Care field team and Director of Medical Education at a large pharmaceutical company.
She is published in journals including Pharmacotherapy, Drug Information Journal, Breast Cancer-Targets and Therapies, DIA Forum,
and Am Journal of Managed Care Pharmacy. She published a book, Bridging Scientific Knowledge: The Role of the Medical Science Liaison
in 2009, and she contributed a chapter to Erin Albert’s 2008 book and
2011 e- book, Medical Science Liaisons A to Z.

Beverley Huggins

Director of Global MSL Practices & Medical Training
GSK

Bev has worked in the Pharma industry for 20 years with experience in both commercial and medical leadership roles. Commercial Leadership roles included sales management, market development, sales performance coach and senior marketing for Respiratory. From a Medical Leadership perspective Bev has set up a team of field based MSLs in the UK alongside a medical information HUB and the addition of a new “expert medic field role”. Now leading the Global MSL Organisation at GSK. Bev is passionate about keeping the patient at the heart of all activities.

Amir Lass

Medical Director
SLA Pharma, UK

Amir graduated from Hebrew University medical school in Jerusalem, Israel in 1986 and completed his training in obstetrics and gynaecology in 1994, when he moved to the UK for a 2 years fellowship specializing in fertility and IVF at the Hammersmith Hospital London. He then continued with clinical practice at Bourn Hall Clinic till 2001 when he started his career in the pharmaceutical industry for the last 18 years in a wide range therapeutic areas with increasing responsibility and his recent permanent position was VP medical affairs Teva Europe. He has been working in a few small and large companies as medical consultant in medical affair and clinical development.

Julie Greely

National Director – Health Economics & Outcomes Research,
Medical Affairs, Americas
Astellas, USA

Julie has been in the Pharmaceutical Industry since 1995 and seen significant changes and growth within the role of Field Medical.  As a National Director at Roche, Novartis, Pfizer, and currently Astellas, she has experienced the need to ensure the relevance of Field Medical teams in an evolving landscape. Strategy for on-going development and support of these teams has been her passion for 20 years.

Asad Khan

European Medical Director
Norgine, UK

Dr. Asad Khan is a UK licensed Pharmaceutical Physician and a Chartered Marketer. Asad has around 20 years’ experience of the Pharmaceutical industry gained in a variety of disciplines and functions.
After spending 6 years in marketing, both at national and international levels, Asad moved into Medical Affairs more than 13 years ago. In the past, Asad has led regulatory teams and has been the compliance head for a major pharma company.
Currently, Asad works at Norgine as European Medical Director and looks after all Norgine EU medical teams compromising of around 50 highly committed professionals spread all over Europe.
Asad is a Fellow of Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and is on the UK GMC specialist register for Pharmaceutical medicine. He is also a Member of the Chartered Institute of Marketing, UK. Asad also has formal qualifications in Marketing, Business, Pharmacovigilance and Law.

Maarten Van Baelen

Market Access Director
Medicines for Europe, Belgium

The goal of « Medicines for Europe » (formerly EGA) is to improve health by ensuring better access to treatment for patients in Europe and beyond. As Market Access Director, the objective of Maarten’s team is to shape in the EU a dynamic and sustainable market situation that enables fast and fair pricing and reimbursement for generic, biosimilar and value-added medicines.
Maarten joined « Medicines for Europe » in 2011 as Medical Affairs Manager with responsibilities in the areas of fighting Falsified Medicines and Pharmacovigilance. In his life before the association, he worked in the pharmaceutical industry providing pharmacovigilance consultancy and in the medical device industry liaising with Key Opinion Leaders. He combined these roles while working weekends in a community pharmacy. Maarten is a pharmacist by education and holds an MBA from “Solvay Brussels School of Economics and Management” and “École des Ponts Paris Business School”.

Sherry Dunbar

Senior Director, Global Scientific Affairs
Luminex Corporation, USA

Dr. Dunbar received a B.S. degree in Microbiology and Immunology from the University of Maryland, a Ph.D. in Medical Microbiology and Immunology from the University of South Alabama, College of Medicine, and a MBA from the University of Maryland. She completed post-doctoral fellowship training in Clinical and Public Health Microbiology at Baylor College of Medicine and was the Laboratory Director of Virus Reference Laboratory in Houston, Texas.
Dr. Dunbar joined Luminex as a Senior Scientist in 1999 and served as Senior Director of the Biology Research and Development group for eight years. She is currently the Senior Director of Global Scientific Affairs for Luminex. Dr. Dunbar has developed hundreds of multiplexed assay panels for proteins, nucleic acids and other biomolecules on the xMAP Technology platform. She has presented more than 20 abstracts at scientific conferences and has more than 30 publications in the peerreviewed literature.

Catherine Billoët

Medical Affairs Director, World Business Line
Air Liquide Healthcare International, France

Medical Doctor Graduated from Pité Salpêtrière University (Laureat Bronze Medal); trained in Anesthesia & Resuscitation. Since 2012 Director of Medical Affairs for Home healthcare and Medical Gases World Business Lines Air Liquide Healthcare International activities. Joined internally the "pharma" industry in 2007. Skills in transforming medical needs in medical products development/ marketing/ communication programs. Background: 20 years in Strategy / Communication Consultancy for the pharma industry, in all therapeutic fields (Primary Care, Specialties, Hospital), and for Major medical Communication Companies such as Burson Marsteller; Boz; Belier Rive Gauche; Saatchi&Saatchi Heathcare; Publicis Healthcare

Erik Briers

Alternate Patient member of the
EMA Committee on Advanced Therapies (CAT)
Patient Advocate, Belgium

Erik Briers received a Doctorate of Science in Chemistry from KU Leuven. He was a Guest lecturer on principles of immunology and drug design in the treatment of cancer at the University of Leuven.
Erik has been active since 2012 with the European Cancer Patient Coalition as Executive Director and since 2002 with Europa Uomo – a
Prostate Cancer focused patient organisation. For many years Erik is involved as a patient advocate in working with the EMA (PCWP, SAG and CAT). Erik is also Founder and CEO of Beta Ventures, whose main activities are publishing and editing Focus Diagnostica (a magazine on in vitro diagnostics) & organising continued education for clinical pathologists.

Alastair Kent OBE

Ambassador, Genetic Alliance, UK
Member, NHS England Rare Diseases Advisory Group

Alastair Kent OBE is the past Director, now Ambassador of Genetic Alliance UK– the national charity of over 150 patient organisations, supporting all those affected by genetic conditions. Genetic Alliance UK’s mission is to promote the development of the scientific understanding of genetics and the part that genetic factors play in health and disease, and to see the speedy transfer of this new knowledge into improved services and support for patients. Alastair is the Chair of Rare Disease UK (RDUK) the national alliance for people with rare diseases and all who support them. RDUK has over 1,200 members including over 220 patient organisations, health professionals, researchers, the pharmaceutical industry and individual patients and families. Alastair has worked in the field of genetic and rare disease healthcare for over 20 years. Alastair represents the interests of patients on numerous platforms; he is the president of the European Genetic Alliances Network (EGAN), Immediate Past Chair of the European Platform for Patient Organisations, Science and Industry (EPPOSI) and the EU Committee of Experts on Rare Diseases amongst others. He has previously been a member of the Orphan Medicinal Products Committee and Committee for Advanced Therapies at the European Medicines Agency and a member of the Human Genetics Commission.

Marcus D. Wilson

President
HealthCore, (an Anthem Inc. Company), USA

Marcus Wilson is President of HealthCore, Anthem’s wholly-owned outcomes research subsidiary. He has been extensively involved in efforts to utilize real-world data environments to accelerate healthcare evidence development and to facilitate clinical decision support for more than 20 years.  Prior to co-founding HealthCore in 1996, Dr Wilson spent seven years within an integrated delivery system owned by BCBS of Delaware where he oversaw the physician and patient clinical decision support, pharmacy policy and clinical trials programs. Dr. Wilson is active on a number of boards and national committees including serving as chair of the Joint Research Committee for the Academy of Managed Care Pharmacy (AMCP) & the AMCP Foundation; member of the FDA Sentinel Initiative Planning Board; Board of Directors for the Center for Medical Technology Policy (CMTP); a member of the Dean’s Roundtable, College of Science, Virginia Tech; and member of the Planning Committee for the National Academy of Medicine’s upcoming Real-World Evidence Workshop Series that is being conducted for FDA in response to the 21st Century Cures legislation. Dr Wilson is a past member of numerous boards and committees including the Board of Directors for the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), the eHealth Initiative and is former chair of the Innovations in Medical Evidence Development (IMEDS) Steering Committee, Reagan-Udall Foundation for the FDA. Dr. Wilson received his Bachelor of Science in Biochemistry from Virginia Tech and his Doctor of Pharmacy degree from the Medical College of Virginia. He completed a residency in Family Medicine at the Medical University of South Carolina prior to joining the faculty at the Philadelphia College of Pharmacy (now the University of Sciences in Philadelphia).

Rosa Giuliani

Medical Oncologist
The European Society for Medical Oncology (ESMO), Italy

Rosa Giuliani works as medical oncologist at S. Camillo Forlanini Hospital in Rome. Her main areas of interest include breast cancer, clinical and regulatory development of new drugs. She dedicated several years specializing in the treatment of breast cancer at the Breast Unit of the Jules Bordet Institute in Brussels (2001-2003), at the Cancer Cell Biology Dept of Hammersmith Hospital (2005-2006) and at the Breast Unit of Charing Cross Hospital (2008) in London. In 2011-12 she temporarily joined the European Medicines Agency (EMA) as national expert on secondment. Since 2012 she is a core member of the EMA scientific advisory group in oncology. In 2012 she joined the Public Policy Committee of ESMO and on behalf of ESMO participates to the activities of the EMA Healthcare Professional Working Party (HCPWP). Since the end of 2013 she represents ESMO in the Stakeholder Forum (Healthcare Providers group) of EUnetHTA (European Network for Health Technology
Assessment ). Rosa Giuliani firmly believes that early dialogue between all relevant stakeholders (patients, patients advocates, HCPs, industry, regulatory and HTA bodies) is the key element which may lead to the timely, equitable and affordable development of new drugs and medical technologies.

Suzanna Lawrence

General Manager
Tardis Medical Consulting, UK

Suzanna is a founding partner and General Manager of Tardis Medical Consultancy, a trading division of Publicis Healthcare Communications Group Ltd. Suzanna is an insightful coach and business performance consultant of many years’ experience, consistently demonstrating an ability to enable people to achieve more than they ever thought they were capable of. She is most interested in delivering measurable improvements in individual, team and organisational performance through learning and development solutions, tailored to individual client’s needs. Her recent successes have been in coaching senior executives to improve their presentation, facilitation and communication skills, particularly with respect to defining and clearly articulating a compelling vision for their business. She has worked with their teams to improve their time and energy management, assertiveness, personal confidence and resilience, particularly in times of significant change. Suzanna combines her coaching and facilitation skills with practical business acumen built up over 20 years in the pharmaceutical industry preceded by 10 years in semiconductor engineering. Over the years, Suzanna has had hands-on practical experience of commercial and medical leadership, marketing management, market research, performance coaching and major event management including the delivery of many inspirational presentations to large audiences. She is an NLP Practitioner and Fellow of the Institute of Sales and Marketing Management.

Leanne Larson

Corporate VP, Observational Research
PAREXEL

Leanne has over 25 years’ experience in health care, featuring extensive work in pharmaceutical product development and marketing, and in health care technology and operational consulting. Since 1993, Leanne has been an industry leader in developing and leading patient registries and other RWE programs, and in advancing the science and application of outcomes research throughout the pharmaceutical, biotech, and medical device industries.

Tessa Pugh

Director
PharmaReview, UK

Tessa graduated with a degree and professional diploma in Strategic Marketing in the early 1990s. Her formative years were spent in client facing roles at advertising agencies, including Saatchi and Saatchi and FCB in London, where she looked after Financial Services and FMCG clients. Tessa launched PharmaReview 7 years ago, with Dr Ralph Carter.  PharmaReview is a   specialist provider of outsourced copy review services to the pharmaceutical industry.  Its  mission is to reduce the time and cost which internal copy review places on senior members of  clients’ medical, regulatory and commercial teams while maintaining the highest levels  of regulatory adherence and compliance. Tessa is a highly experienced practitioner in ZincMAPS and Veeva Vault PromotMats functionaility and a copy review process expert.

Richard Macaulay

Principal Consultant, (Pricing and Market Access)
Parexel, UK

Richard Macaulay, Ph.D., is a Principal Consultant with PAREXEL Access in London. Richard has specialized for seven years’ in regulatory and market access strategy, in particular helping obtain regulatory and payer approval for treatments lacking Phase III trial data, with a specialist expertise in oncology treatments and rare diseases. He has completed over 40 research presentations in his field, including posters, webinars, conference presentations, and manuscripts. Richard has a PhD from University College London, and a BA (Hons) in Medicine from the University of Cambridge.  

Giovanni Fiori

Managing & Scientific Director
MediNeos

A PhD in Human Populations Biology (Bologna University) Fiori has also a master’s degree in Public Health from the Catholic University “Sacro Cuore” (Rome). He managed epidemiological research campaigns in the framework of large international cooperation programs in Central Asia. Since its foundation, he is the Scientific Director of Medineos (previously MediData), in charge to define the strategy for designing and conducting more than 120 local and international studies collecting Real World Data for Life Science Industries and no-profit organizations. Since 2005 he has been coordinating the “Observational Studies” Working Group of the Society for Applied Pharmacological Sciences  where he has also been a member of the Board of Directors. He is the chairman of  EUCROF (European CRO Federation) “Late Phase” working group. He teaches regularly at the Master in Clinical Research of Milano Bicocca University. Invited speaker at several congresses, he has been authored or co-authored over one hundred scientific papers and articles.

Tina Moen

Deputy Chief Health Officer
IBM Watson Health

Dr. Tina Moen has spent the last 15 years in healthcare technology providing clinical leadership to colleagues and clients around the world.  Tina is Deputy Chief Health Officer within IBM Watson Health with a key focus in value based care, evidence-based medicine, pharmacy, and life sciences. Previously, she was VP Client Strategy for Health Language within Wolters Kluwer Health.  Prior to that, Tina held a variety of roles at Truven Health Analytics, including VP Provider Analytics and Chief Clinical Officer for the Provider segment.

Dr. Moen received her Doctor of Pharmacy from Creighton University. Early in her career, she was a clinical pharmacist in a variety of specialty areas, including pediatrics, hospice, HIV, and transplant.

Louise Picken

Senior Scientific Director
Complete HealthVizion

Louise Picken is a Senior Scientific Director at Complete HealthVizion, a medical communications and strategic consultancy in the McCann Health network. Louise has a PhD and 4 years of research experience with a small biotechnology company. She has 18 years of experience in strategic medical communications throughout the drug development life cycle and across a wide range of therapy areas and communication channels. Louise has a passion for translating deep insight into communications strategies and innovative multichannel medical education that ultimately improve the lives of patients.

Robert Poole

Director of Scientific Services
Complete HealthVizion

Robert Poole is Director of Scientific Services at Complete HealthVizion, a medical communications and strategic consultancy in the McCann Health network. Robert has a PhD and 10 years of experience working in academic biochemistry research. He has nearly 20 years of experience in strategic healthcare communications, working collaboratively with clients across a broad range of therapy areas and communication channels to translate medical science to meaningful communications that change lives. Robert has a particular interest in taking behavioural science out of its established areas and applying it more broadly to drive smarter, more effective communications for healthcare professionals and patients.

Maryna Kolochavina

Project Director, Real World & Late Phase
Syneos Health

Maryna Kolochavina has 13+ years of extensive experience in post-marketing research, project management, studies remediation, early access to unlicensed medication and market launch, quality assurance, accelerated pathways and expedited approvals, line extensions. Her most recent experience was for conducting observational studies varying in size and locations (from 150 to 100,000 patients to single country projects in rare diseases). She oversees clinical projects and observational studies varying in study/project phases (I, IIA/IIB, IIIA/IIIB, IV) and designs, such as disease and product observational registries with prospective and retrospective data collection, pregnancy registries, observational FUP, retro chart review studies; compassionate use programs (including Named Patient Program, Expanded Access Programs, ATU, Special Access, IND); safety surveillance studies (including active and passive surveillance studies, descriptive drug utilization studies, PASS, PAES); non-interventional studies (NIS) with ePRO, HEOR and EPI modules; ATMP and stem cells studies, device studies.

Member of European Forum for GCP, ACRP, BARQA, ASQ, PMI

Author of 30+ publications

Previous Attendees at MedAffairs Leaders Forum - Zürich, Switzerland, 2017

Company
Job Title
Adelphi Communications
Development Director
Adelphi Communications
Director Scientific Services
Adelphi Communications
Director
Aegerion Pharmaceuticals
Medical Affairs Director
Angelini Farmaceutica
Medical and Business Development Director
Angelini Farmaceutica
Medical Advisor
AstraZeneca
Senior Director Emerging Portfolio and Real World Evidence
AstraZeneca
Capabilities Lead
AstraZeneca
Lead Medical Affairs Oncology
AstraZeneca
Senior Medical Affairs Manager
AstraZeneca
Medical Scientific Project Manager
Bayer AG
Senior Medical Affairs Physician
Biogen
Head of Global Medical Learning and Development
Biogen
Head of Medical Operations, Biosimilars
Biogen Idec
Medical Director Europe & Canada | MS franchise
Boehringer Ingelheim
Deputy International Head Therapeutic Area Medicine Oncology
Boehringer Ingelheim
Medical Lead Cardiovascular
Boehringer Ingelheim
Medical Director
Boehringer Ingelheim
Head of Medical Science Liaisons
Boston Scientific
Medical Affairs Manager EP, Europe
Bristol-Myers-Squibb
Global Field Medical Director
BSN Medical
SVP Scientific & Regulatory Affairs
Cascadian Therapeutics
Medical Director
Celgene
Head of Medical Affairs Haematology/Oncology, EMEA
Celgene
Ass Director Medical Affairs
Celgene
RML Head Haematology
Celgene B.V.
Senior MSL Manager
Celgene B.V.
Medical Advisor
Cell Medica LTD
Director Medical & Scientific Affairs
Chiesi
Medical Director
Chiesi Farmaceutici S.P.A.
Global Medical Affairs Head
Cook Regentec
Director Medical Affairs
Costello Medical
Analyst – Medical Affairs
Costello Medical
Project Consultant – Medical Affairs
CRUK/MRC Oxford Institute for Radiation Oncology , University of Oxford
Professor of Clinical Oncology
Daiichi Sankyo Europe
Director Medical Affairs Antithrombotic & Cardiovascular Therapeutic Area
Edwards Lifesciences
Associate Medical Manager
Eisai
Senior Vice President, Chief Medical Officer
Eli Lilly
Medical Lead Oncology
Eli Lilly
Real World Evidence Scientist
Eli Lilly and Company
Director of Real World Evidence Medical Affairs, Europe Canada (EUCan) Region
Ferring Pharmaceuticals
Senior Director, Medical Affairs - Orthopaedics
Finnish Red Cross Blood Service
Medical Director
Fishawack Communications GmbH
President
Fishawack Communications GmbH
Managing Director
GSK
Senior Vice President, Head Worldwide Medical Affairs
GSK
Medical Director
Helsinn
Medical Affairs Manager
Heraeus
Head of Marketing
ICTA PM
Business Development Director
INC Research
Executive Director, Real World Strategy
INC Research
VP, Real World & Late Phase
INC Research
Director
Innovative Strategic Communications
Principal/Owner
Innovative Strategic Communications
Client Services
Janssen
Head of Medical Evidence Generation
Janssen
Medical Program Lead
Janssen Cilag NV
Medical Affairs Manager
Janssen Cilag NV
Medical Advisor
Janssen Cilag NV
Medical Advisor
Janssen Cilag NV
Medical Advisor Hematology
Janssen-Cilag
Medical Scientific Liaison Manager
Kantar Health
Senior Director
Kantar Health
Senior Director RWE NIS
Kantar Health
Client Consultant RWE
Kantar Health
Client Consultant RWE
Kyowa Kirin
Country General Manager
Kyowa Kirin
Medical Director
Kyowa Kirin International
International Medical Affairs Manager
Kyowa Kirin International
International Medical Affairs Director
Laboratorios Dr. Esteve
Medical Unit Manager
McCann Complete Medical Ltd
Senior Client Services Director
MCPHS University
Post-doctoral Fellow
MediNeos
International Business Developer
Molteni dei Fratelli Alitti SpA
Medical Affairs Manager
Monocl
Sales Director
National Institute for Health and Care Excellence (NICE)
Senior Scientific Adviser – IMI GetReal Research and Development
Nobel Biocare
Associate Manager Scientific Communication
Nobel Biocare
Project Manager Medical Writing
Nobel Biocare
Project Manager Medical Writing
Novartis
MSL Manager Cardio Metabolic
Novartis
Field Medical Excellence Head Turkey, Middle East and Africa
Novartis
Director GMA Office
Nutricia Advanced Medical Nutrition UK
Head of Adult Medical Services UK
Parexel
Vice President and Global Head, Observational Research
Parexel
Vice President and Head, Pricing and Market Access
Parexel
Senior Director, Business Development
Parexel International
Vice President
PharmaReview Ltd
Director
PharmaReview Ltd
Director
Pharming Group
Vice President Medical Affairs
PTC Therapeutics
Senior Medical Director Cystic Fibrosis, EMEA
Puma Biotechnology
Clinical Science Liaison
QuintilesIMS
Director, Real World Insights
Roche Diagnostic Corporation
Director, Medical and Scientific Affairs
Roche Diagnostics
International Medical Affairs Leader
Roche Diagnostics International Ltd.
Senior Medical Affairs Manager
Sandoz
Chief Medical Officer, Global Product Development
Sanofi Genzyme
VP & Head, Medical Affairs NA, Rare Diseases
Sanofi Genzyme
Senior Director, Head Rare Disease US MSL
Servier
Head of Medical affairs
Shire
Medical Director, Head Global Medical Affairs Strategy Immunology
Shire
Publications Lead
Shire
Medical Communications
Shire
Associate Director Global Medical Communications
Shire
Medical Communications
Shire
Medical Communications
Sobi (Swedish Orphan Biovitrum)
Senior Medical Director
Succinct Medical Communications
Account Director
Succinct Medical Communications
Account Manager
Takeda
Associate Director Global Medical Information - Emerging Markets Lead
Takeda
Medical Affairs Europe and Canada (EUCAN) Global Medical Affairs
Takeda
Lead Study Management
Takeda
Head of Data Generation
Takeda AG
Lead Contracts and Relations Management
Takeda Pharmaceuticals
Vice President Medical Affairs Europe & Canada
Terumo BCT
Medical Affairs & Therapy Awareness Manager
Terumo BCT
Clinical Pathologist
Terumo BCT
Director Global Medical & Scientific Affairs
Teva
Global Director, Specialty Life Cycle Management, Global Specialty Medicines,
The National Association of Primary Care (NAPC)
Member of Council
The Patients’ and Consumers’ Working Party, EMA
Member
Thuasne
Medical Director
UCB BIOSCIENCES
Global Clinical Lead Vimpat & Keppra Seizure Freedom Mission Patient Value Unit Neurology
University of Oxford
Lecturer of Medicine
Valeant
Director, Medical Science
Veeva Systems
Director, Medical Strategy
Veeva Systems
Manager, Field Marketing Europe
Veeva Systems
Senior Marketing Manager
Veeva Systems
Senior Solution Consultant
Vifor Pharma
Medical Affairs Manager
Vifor Pharma
Medical Affairs Trainee
Vifor Pharma Ltd.
Global Lead Publications and Medical Communications
Vifor Pharma Ltd.
Global Lead Medical Trials
Vifor Pharma Ltd.
Global Medical Lead Broncho-Vaxom
Vifor Pharma Ltd.
Global Medical Lead Uro-Vaxom & Doxium
Vifor Pharma Ltd.
Global Medical Lead
Vifor Pharma Ltd.
Medical Affairs Lead

Related Videos

Presentation

Leading MSLs to the best of their potential

Related topics: Medical Affairs & Stakeholder Engagement, Medical Science Liaison
Availability: FREE
  • Internal training
  • Engagement tool
  • Keeping the conversation going
Speakers

Annie Rankin
Client Partnerships Lead
Succinct Medical Communications

Gavin Kenny
Account Director
Succinct Medical Communications

Presentation

The power of consistent communication with HCPs and patients

Related topics: Medical Affairs & Stakeholder Engagement, Patient-Centricity & Care
Availability: FREE
  • Keeping consistency in communications with both HCPs and patients to maximise high quality patient-HCP conversations
Speakers

Katie Corbin
Managing Director
Succinct Medical Communications

Richard Jones
Patient Services Director
The Earthworks (an OPEN Health Company)

Pricing & Registration

Event Documentation (including Slides) & Post-Event Report
All Delegates
399 EUR
Video Recordings, Event Documentation (including Slides) & Post-Event Report
All Delegates
799 EUR
3 Day Event
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Solution Provider/Consultant
1 Delegate
2790 EUR
2 Delegates
2511 EUR
10% discount
3 Delegates
2371 EUR
15% discount
4+ Delegates
2232 EUR
20% discount
Academic
1 Delegate
1150 EUR
2 Delegates
1150 EUR
3 Delegates
1150 EUR
4+ Delegates
1150 EUR
Payer/HTA/Regulator
1 Delegate
499 EUR
2 Delegates
499 EUR
3 Delegates
499 EUR
4+ Delegates
499 EUR
2 Day Event
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Solution Provider/Consultant
1 Delegate
2290 EUR
2 Delegates
2061 EUR
10% discount
3 Delegates
1946 EUR
15% discount
4+ Delegates
1832 EUR
20% discount
Academic
1 Delegate
950 EUR
2 Delegates
950 EUR
3 Delegates
950 EUR
4+ Delegates
950 EUR
Payer/HTA/Regulator
1 Delegate
499 EUR
2 Delegates
499 EUR
3 Delegates
499 EUR
4+ Delegates
499 EUR